Mancia Giuseppe, Giannattasio Cristina
aIRCCS Istituto Auxologico Italiano, Milan and University of Milano-Bicocca bMilano-Bicocca University and Cardiology IV, Niguarda Ca Granda Hospital, Milan, Italy.
J Hypertens. 2015 Jan;33(1):33-43. doi: 10.1097/HJH.0000000000000424.
Prevalence of isolated systolic hypertension increases with age, due to progressive elevation of SBP, and is a major risk factor for cardiovascular morbidity and mortality. Extensive research has shown that lowering SBP improves cardiovascular outcomes in patients with isolated systolic hypertension, yet SBP control rates remain largely inadequate regardless of antihypertensive treatment. Arterial stiffness is a major determinant of elevated SBP resulting from structural changes in the vascular system, mediated by neurohormonal alterations that occur with vascular ageing. Clinical data have demonstrated an independent association between arterial stiffness and cardiovascular outcomes. Therefore, arterial stiffness has the potential to be an important therapeutic target in the management of isolated systolic hypertension. Current antihypertensive treatments have limited effects on arterial stiffness, so the development of new treatments addressing neurohormonal alterations central to vascular ageing is important. Such therapies may represent effective strategies in the future management of SBP.
单纯收缩期高血压的患病率随年龄增长而增加,这是由于收缩压逐渐升高所致,并且是心血管疾病发病和死亡的主要危险因素。广泛的研究表明,降低收缩压可改善单纯收缩期高血压患者的心血管结局,然而,无论采用何种抗高血压治疗,收缩压控制率仍然普遍不足。动脉僵硬度是血管系统结构变化导致收缩压升高的主要决定因素,这是由血管老化时发生的神经激素改变介导的。临床数据表明动脉僵硬度与心血管结局之间存在独立关联。因此,动脉僵硬度有可能成为单纯收缩期高血压管理中的一个重要治疗靶点。目前的抗高血压治疗对动脉僵硬度的影响有限,因此开发针对血管老化核心的神经激素改变的新治疗方法很重要。此类疗法可能代表未来收缩压管理的有效策略。